SBIR-STTR Award

Ratiometric Quantification of Targeted Methylated DNA sites using MM-LAMP-OSD & Detection Devices
Award last edited on: 8/30/2021

Sponsored Program
STTR
Awarding Agency
DOD : Army
Total Award Amount
$166,500
Award Phase
1
Solicitation Topic Code
A19B-T013
Principal Investigator
Robert C Chin

Company Information

Fabrico Technology Inc (AKA: Gene Xpress Informatics)

13091 Pond Springs Road
Austin, TX 78729
   (512) 219-8588
   N/A
   www.fabricotech.com

Research Institution

University of Texas at Austin

Phase I

Contract Number: W81XWH-20-P-0037
Start Date: 2/12/2020    Completed: 11/11/2020
Phase I year
2020
Phase I Amount
$166,500
The DoD is seeking technology and systems to quantify regulating DNA methylation transcriptional activators or repressors, and chromatin remodeling enzymes. Fabrico Technology, Dr. Sanchita Bhadra, and Professor Andrew Ellington of the University of Texas at Austin, proposes to develop an in-field detection platform based upon Mismatch Methyl Loop Mediated Isothermal Amplification-One-step Strand Displacement (MM-LAMP-OSD), a method that should prove capable of the quantitative identification of methylated nucleotides at targeted sites. MM-LAMP-OSD is dependent upon the innovation that antibodies can specifically recognize methylated nucleotides where a mismatch occurs resulting in a steric block to isothermal amplification via LAMP. Fabrico Technology has developed a patent pending LAMP-OSD detection system which is ideally suited for determining quantitatively this MM-LAMP-OSD assay ratiometrically. In this proposal effort, Fabrico and the Ellington Lab intends to modify and optimize the device to ratiometrically measure multiple MM-LAMP-OSD assays. By ratiometrically comparing non-fluorescent methylated DNA sequences to the fluorescence of non-methylated DNA sequences, it possible to quantitatively determine methylation sites in nucleic acid bases from a mammalian genome resulting in a novel method for monitoring any stage of a disease, onset, clinical course, or response to treatment.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----